hepatitis

[Hepatology] Hepatitis B virus infected HepG2-NTCP were treated with tenofovir disoproxil fumarate, Toll-like receptor 7/8 agonists, TLR7/8 conditioned media collected from immune cells, or RNAi using short-interfering RNAs.

[mBio] Researchers explored the roles of hepatocyte-derived exosomal microRNAs and B cell activating factor in the extrahepatic diseases of hepatitis C virus infection.

[Seal Rock Therapeutics, Inc.] Seal Rock Therapeutics, Inc. announced completion of the single ascending dose portion of its Phase I clinical trial of SRT-015, a next-generation, liver-selective inhibitor of Apoptosis Signal-regulating Kinase 1 for non-alcoholic steatohepatitis (NASH) and other liver diseases such as alcoholic hepatitis.

[Clinica Chimica Acta] Investigators discuss the current state of non-alcoholic fatty liver disease metabolites, gut micro-environmental changes, and the further challenges in digital metabolomics profiling.

[Laboratory Investigation] The authors investigated the mechanism as to how the hepatitis B virus virions pass through layers of the trophoblast.

[Nature Medicine] Investigators evaluated the safety and activity of an antisense oligonucleotide targeting hepatitis B virus (HBV) RNA in both treatment-naïve and virally suppressed individuals with chronic HBV infection.